Guo, Chenchen, Wan, Ruijie, He, Yayi, Lin, Shu-Hai, Cao, Jiayu, Qiu, Ying, Zhang, Tengfei, Zhao, Qiqi, Niu, Yujia, Jin, Yujuan, Huang, Hsin-Yi, Wang, Xue, Tan, Li, Thomas, Roman K., Zhang, Hua, Chen, Luonan, Wong, Kwok-Kin, Hu, Liang and Ji, Hongbin (2022). Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat. Cancer, 3 (5). S. 614 - 652. BERLIN: NATURE PORTFOLIO. ISSN 2662-1347

Full text not available from this repository.

Abstract

Ji and colleagues demonstrate that metabolic reprogramming in SCLC underlies chemotherapy resistance, resulting in an actionable dependency on the mevalonate pathway in tumor cells, which can be targeted using statins to revert chemoresistance. Small cell lung cancer (SCLC) lacks effective treatments to overcome chemoresistance. Here we established multiple human chemoresistant xenograft models through long-term intermittent chemotherapy, mimicking clinically relevant therapeutic settings. We show that chemoresistant SCLC undergoes metabolic reprogramming relying on the mevalonate (MVA)-geranylgeranyl diphosphate (GGPP) pathway, which can be targeted using clinically approved statins. Mechanistically, statins induce oxidative stress accumulation and apoptosis through the GGPP synthase 1 (GGPS1)-RAB7A-autophagy axis. Statin treatment overcomes both intrinsic and acquired SCLC chemoresistance in vivo across different SCLC PDX models bearing high GGPS1 levels. Moreover, we show that GGPS1 expression is negatively associated with survival in patients with SCLC. Finally, we demonstrate that combined statin and chemotherapy treatment resulted in durable responses in three patients with SCLC who relapsed from first-line chemotherapy. Collectively, these data uncover the MVA-GGPP pathway as a metabolic vulnerability in SCLC and identify statins as a potentially effective treatment to overcome chemoresistance.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Guo, ChenchenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wan, RuijieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
He, YayiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lin, Shu-HaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cao, JiayuUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Qiu, YingUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhang, TengfeiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhao, QiqiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niu, YujiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jin, YujuanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huang, Hsin-YiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wang, XueUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tan, LiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomas, Roman K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhang, HuaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chen, LuonanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wong, Kwok-KinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hu, LiangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ji, HongbinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-691937
DOI: 10.1038/s43018-022-00358-1
Journal or Publication Title: Nat. Cancer
Volume: 3
Number: 5
Page Range: S. 614 - 652
Date: 2022
Publisher: NATURE PORTFOLIO
Place of Publication: BERLIN
ISSN: 2662-1347
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
METABOLISM; INHIBITION; PLASTICITY; APOPTOSIS; AUTOPHAGY; REVEALS; SUBTYPE; BIOLOGY; DRUGS; ROSMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69193

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item